February 5, 2009
We said a while back that there would be more surprises coming out of Research In Motion’s options backdating scandal. A big one came today. Two years ago, I raised a number of concerns about Research In Motion’s corporate governance, describing it as a relic of the past. As its backdating scandal unfolded, I expressed serious [...]
Read the full article →
April 14, 2008
Biovail, Canada’s largest publicly traded drug manufacturer, has been in the news probably more than it would like lately. It has had problems with its financial performance, with securities regulators and with its former CEO, Eugene Melnyk. When Mr. Melnyk was at the helm of the company, it was not exactly known for its exemplary [...]
Read the full article →